The only earbuds on the market that analyze
your hearing profile to generate truly custom sound made just for
you
Masimo (NASDAQ: MASI), a global leader in innovative noninvasive
monitoring technologies, and Denon, a pioneer in audio technology
with over a century of audio expertise, proudly unveil the latest
evolution of its acclaimed Denon PerL™ and Denon PerL Pro™ True
Wireless earbud lineup with the introduction of White PerL. Denon
PerL represents the epitome of personalized audio listening.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240516300869/en/
Denon PerL™ and PerL Pro™ (Photo:
Business Wire)
The two Denon PerL models are engineered with Masimo’s
proprietary Adaptive Acoustic Technology™ (AAT™) to deliver the
only earbud that puts hearing personalization at the forefront of
the listening experience. Masimo AAT works by detecting an
individual’s inner ear response from carefully curated sound
frequencies sent into the ear canal and then creating a custom
hearing profile based on each individual’s hearing sensitivities –
helping to enhance sound depth, detail, and clarity for a superior
listening experience.
Joe Kiani, Founder and CEO of Masimo, stated, “PerL continues to
propel us into a new era of personalized listening, and Masimo is
proud to lead the charge. With our Adaptive Acoustic Technology
integrated into Denon’s PerL earbuds, we’re not just changing the
way we listen to music; we’re revolutionizing the future where
every individual can enjoy sound tailored precisely to their unique
hearing profile, setting a new standard for immersive audio.”
Masimo’s AAT has raised the bar to new heights for personalized
audio. By harnessing Masimo’s expertise, Denon PerL goes beyond
conventional audio tuning, ensuring that each user’s unique hearing
profile is fully understood.
Your Music Tuned Your Way
From person to person, hearing differences impact the listening
experience. Denon PerL with Masimo AAT automatically tunes the
sound based upon each individual’s inner ear response to enhance
sound depth, details, and clarity for a supreme personalized
listening experience. The Denon PerL Headphone app for iOS and
Android simplifies the creation of your personalized hearing
profile through a step-by-step adjustment process. The app also
allows you to adjust listening settings and change your bass and
treble equalization preferences while still using your optimized
hearing profile.
Elevating the Audio Experience with Denon’s
Legacy of Excellence
Drawing from over a century of audio mastery, Denon ensures that
both PerL models embody the brand’s signature sound superiority. By
combining the brand’s renowned signature spacious and vivid sound
with Masimo’s cutting-edge technology, Denon PerL offers unmatched
depth, detail, and clarity every session.
Unparalleled Versatility and Functionality
In addition to personalized sound, the Denon PerL earbuds boast
an array of features designed to adapt to the user’s lifestyle
seamlessly. One of the problems with many earbuds is that they
easily fall off the ear. This problem has been substantially
reduced due to Denon PerL’s unique mechanical design.
Whether immersing oneself in music with active noise
cancellation or staying connected to the surroundings with social
mode, Denon PerL has features to accommodate a variety of
lifestyles. Enjoy advanced functions with Denon PerL Pro such as
spatial audio, which creates a more immersive surround sound
atmosphere in a compact and comfortable format, and adaptive active
noise cancellation that dynamically adjusts to each user’s
environment.
Discover the power of truly personalized listening, as Denon
redefines the audio experience. The new color of Denon PerL and
Denon PerL Pro is now available at www.Denon.com for $199 and $349,
respectively.
@Masimo | #Masimo
About Denon
Denon, a leading manufacturer of premium audio equipment, is
dedicated to delivering the ultimate listening experience to music
lovers worldwide. Since 1910, Denon has been at the forefront of
technological advancements in audio engineering, setting the
standard for high-quality sound systems that are built to last and
cater to the diverse needs of music enthusiasts, from audiophiles
to casual listeners. For more information, visit Denon.com.
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. In addition, Masimo Consumer Audio is home to eight
legendary audio brands, including Bowers & Wilkins, Denon,
Marantz, and Polk Audio. Our mission is to improve life, improve
patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.1
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,2 improve CCHD screening in
newborns3 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.4-7 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,8 and is
the primary pulse oximetry at 9 of the top 10 hospitals as ranked
in the 2022-23 U.S. News and World Report Best Hospitals Honor
Roll.9 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve
Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7®,
Radius PPG®, and Radius VSM™, portable devices like Rad-67®,
fingertip pulse oximeters like MightySat® Rx, and devices available
for use both in the hospital and at home, such as Rad-97® and the
Masimo W1® medical watch. Masimo hospital and home automation and
connectivity solutions are centered around the Masimo Hospital
Automation™ platform, and include Iris® Gateway, iSirona™, Patient
SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo
SafetyNet®. Its growing portfolio of health and wellness solutions
includes Radius Tº®, Masimo W1 Sport, and Masimo Stork™. Additional
information about Masimo and its products may be found at
www.masimo.com. Published clinical studies on Masimo products can
be found at www.masimo.com/evidence/featured-studies/feature/.
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo AAT™ and its
incorporation into the two Denon PerL models. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of
which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as
a result of various risk factors, including, but not limited to:
risks related to our belief that Masimo's unique technologies,
including AAT, as well as the incorporation of such technologies
into Denon Perl Models, contribute to better listening experience;
risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique
advantages; risks related to COVID-19; as well as other factors
discussed in the "Risk Factors" section of our most recent reports
filed with the Securities and Exchange Commission ("SEC"), which
may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether
our expectations will prove correct. All forward-looking statements
included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these statements or the
"Risk Factors" contained in our most recent reports filed with the
SEC, whether as a result of new information, future events or
otherwise, except as may be required under the applicable
securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240516300869/en/
Media Contact: Masimo Matt Whewell 720-838-0691
Matt.whewell@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From May 2024 to Jun 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Jun 2023 to Jun 2024